Ebola antibody treatment, produced in plants, protects monkeys from lethal disease

A new Ebola virus study resulting from a widespread scientific collaboration has shown promising preliminary results, preventing disease in infected nonhuman primates using monoclonal antibodies.

In this week's online edition of the (PNAS), the research team describes a proof-of-concept for using a "cocktail" of , or mAbs, to prevent in rhesus macaques. When administered one hour after infection, all animals survived. Two-thirds of the animals were protected even when the treatment, known as MB-003, was administered 48 hours after infection.

, which causes hemorrhagic fever with human case as high as 90 percent, has been responsible for numerous deaths in central Africa over the past several months. In addition to being a global health concern, the virus also is considered a potential agent. Currently there are no available vaccines or treatments approved for use in humans.

The work is the culmination of more than a decade of effort between government and industry partners. According to lead investigator Gene Olinger, Ph.D., a virologist at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), this consortium of investigators has taken very distinct technologies and combined them to develop a cutting-edge medical countermeasure against a lethal viral disease.

"It is rare that an antiviral compound prevents Ebola with limited to no morbidity in treated animals at any point of treatment following infection by this ," said Olinger. "Until recently, attempts to utilize antibodies to provide protection against Ebola virus have been met with failure. The level of protection against disease that we saw with MB-003 was impressive."

In addition, the production method used in this study offers the potential to make an economical and effective medical countermeasure, according to the authors. Initially developed as a monoclonal antibody cocktail in the mouse model, MB-003 was successfully humanized and then produced in the tobacco plant-based production system.

"We were pleased to see how well the humanized mAbs of MB-003 performed," said Larry Zeitlin, Ph.D., president of Mapp Biopharmaceutical and senior author on the study. "We also were pleasantly surprised by the superiority of the plant-derived mAbs compared to the same mAbs produced in traditional mammalian cell culture."

Further improvement in antibody efficacy was developed at Kentucky BioProcessing (KBP). Using a fully automated production system that operates in accordance with good manufacturing practices (GMP), antibody is produced in a tobacco plant system. This new development process significantly decreases the amount of time required for production, increases the quantity of antibody produced, and slashes the cost of manufacturing, according to Barry Bratcher, chief operating officer of KBP and co-author on the PNAS study.

"Our GMP facility can generate a new antibody lot in two weeks to rapidly address new threats and new outbreaks," said Bratcher.

Olinger said efforts are underway to advance MB-003 to clinical safety testing as his team at USAMRIID continues to determine the true therapeutic capability of the cocktail.

add to favorites email to friend print save as pdf

Related Stories

Research team identifies receptor for Ebola virus

May 02, 2011

A team of researchers has identified a cellular protein that acts as a receptor for Ebola virus and Marburg virus. Furthermore, the team showed that an antibody, which binds to the receptor protein, is able ...

Recommended for you

Mystery of the reverse-wired eyeball solved

3 hours ago

From a practical standpoint, the wiring of the human eye - a product of our evolutionary baggage - doesn't make a lot of sense. In vertebrates, photoreceptors are located behind the neurons in the back of the eye - resulting ...

Neurons controlling appetite made from skin cells

3 hours ago

Researchers have for the first time successfully converted adult human skin cells into neurons of the type that regulate appetite, providing a patient-specific model for studying the neurophysiology of weight ...

Quality control for adult stem cell treatment

6 hours ago

A team of European researchers has devised a strategy to ensure that adult epidermal stem cells are safe before they are used as treatments for patients. The approach involves a clonal strategy where stem cells are collected ...

A gene for brain size only found in humans

8 hours ago

About 99 percent of human genes are shared with chimpanzees. Only the small remainder sets us apart. However, we have one important difference: The brain of humans is three times as big as the chimpanzee ...

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

PinkElephant
not rated yet Oct 15, 2012
efforts are underway to advance MB-003 to clinical safety testing as his team at USAMRIID continues to determine the true therapeutic capability of the cocktail
Right. I can just imagine it now:

Sir, we need a few dozen "volunteers" to infect with Ebola so we can test this new treatment...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.